A phase 1 study of prasugrel in patients with sickle cell disease: Effects on biomarkers of platelet activation and coagulation

• Published in: Thrombosis research Vol. 133; no. 2; pp. 190 - 195
• Main Authors: Jakubowski, Joseph A., Zhou, Chunmei, Jurcevic, Stipo, Winters, Kenneth J., Lachno, D. Richard, Frelinger, Andrew L., Gupta, Neehar, Howard, Jo, Payne, Christopher D., Mant, Timothy G.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Ltd 01.02.2014
• Subjects: Adenosine Diphosphate - metabolism; ADP; Adult; Anemia, Sickle Cell - drug therapy; Anemia, Sickle Cell - metabolism; Biomarkers; Biomarkers - metabolism; Blood Coagulation - drug effects; Blood Platelets - drug effects; Blood Platelets - metabolism; Female; Hematology, Oncology and Palliative Medicine; Humans; Male; Middle Aged; P2Y12 receptor antagonist; Piperazines - therapeutic use; Platelet Activation - drug effects; Platelets; Prasugrel; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists - therapeutic use; Sickle cell disease; Thiophenes - therapeutic use; Young Adult; CD40L; RBCs; GPIIbIIIa; VOC; EDTA; ADP; P2Y12 receptor antagonist; Prasugrel; SD; TF; TXB2; PD; SCD; Biomarkers; PK; Platelets; Sickle cell disease; red blood cells; tissue factor; P2Y 12 receptor antagonist; pharmacodynamics; glycoprotein IIb-IIIa; sickle cell disease; vaso-occlusive crisis; thromboxane B 2; adenosine diphosphate; ethylenediaminetetraacetic acid; pharmacokinetics; TXB 2; CD40 ligand; standard deviation; thromboxane B; P2Y receptor antagonist; TXB

Prasugrel, a P2Y12 adenosine diphosphate (ADP) receptor antagonist effectively inhibits ADP-mediated platelet activation and aggregation, and may be useful in reducing vaso-occlusive crises in sickle cell disease (SCD). In this study, we assess the effect of prasugrel on biomarkers of platelet activ...